HKU Scholars Hub: Browsing DSpace

Browsing by Author Kim, DW

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 5 of 5

	Title	Author(s)	Issue Date	Views
	Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status Proceeding/Conference:Journal of Clinical Oncology	Gettinger, SN Zhang, S Graeme Hodgson, J Bazhenova, LA Burgers, S Kim, DW Tan, DS Koh, HA Ho, JCM Ramirez, SV Shaw, AT Weiss, GJ Langer, CJ Huber, RM Ahn, MJ Reichmann, WM Kerstein, D Rivera, VM Camidge, DR	2016	176
	Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study Proceeding/Conference:European Society for Medical Oncology (ESMO) Asia Congress, 2017	Mok, T Peter, S Camidge, DR Ou, SH Ahn, JS Tan, EH Li, Z Lee, JS Cho, BC Geater, S Sriuranpong, V Ho, JCM Chan, SH Zeiter, A Balas, B Nueesch, E Mitry, E Morcos, PN Kim, DW	2017	46
	Chronic myeloid leukemia in Asia Journal:International Journal of Hematology	Au, WY Caguioa, PB Chuah, C Hsu, SC Jootar, S Kim, DW Kweon, IY O'Neil, WM Saikia, TK Wang, J	2009	142
	First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology	Zhou, Q Kim, HR Soo, R Chang, GC Chiu, CH Hayashi, H Kim, SW Teraoka, S Goto, Y Zhou, J Lee, VHF Han, B Ho, JCM Kim, DW Lin, CC Lu, S Polli, A Calella, AM Mok, T Wu, YL	2021	29
	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Journal:Blood	Le Coutre, P Ottmann, OG Giles, F Kim, DW Cortes, J Gattermann, N Apperley, JF Larson, RA Abruzzese, E O'Brien, SG Kuliczkowski, K Hochhaus, A Mahon, FX Saglio, G Gobbi, M Kwong, YL Baccarani, M Hughes, T Martinelli, G Radich, JP Zheng, M Shou, Y Kantarjian, H	2008	164

Showing results 1 to 5 of 5